Specifications Table**Subject**Biochemistry, Genetics and Molecular Biology (General)**Specific subject area**Transcriptomics**Type of data**Transcriptome sequences, tables, figure**How data were acquired**Illumina HiSeq 2500 sequencing platform**Data format**Raw Illumina HiSeq 2500 data in FASTQ format**Parameters for data collection**Comparison of *M. smegmatis* cultures treated with an imidazo\[1,2-*b*\]\[1,2,4,5\]tetrazine with untreated control**Description of data collection**Total RNA extracted from six independent samples (three control replicates -- untreated cultures, and three experimental replicates -- treated with an imidazo\[1,2-*b*\]\[1,2,4,5\]tetrazine) subjected to RNA sequencing.**Data source location**Vavilov Institute of General Genetics Russian Academy of Sciences, Moscow, Russia.**Data accessibility**Repository name: NCBI Sequence Read Archive -- SRA\
Data identification number: PRJNA615922\
Direct URL to data: <https://www.ncbi.nlm.nih.gov/bioproject/PRJNA615922>

Value of the Data•These data show for the first time a transcriptomic response of *M. smegmatis* exposed to an imidazo\[1,2-*b*\]\[1,2,4,5\]tetrazine - an anti-tuberculosis drug candidate.•The data may be useful for researchers working on anti-tuberculosis drug development, as it may provide clues on imidazo\[1,2-*b*\]\[1,2,4,5\]tetrazines' mechanism of action.•Analysis of differentially expressed genes upon exposure to imidazo\[1,2-*b*\]\[1,2,4,5\]tetrazine may elucidate additional attractive biotargets in mycobacteria for drug development.

1. Data description {#sec0001}
===================

The dataset presented in this article represents raw RNA-seq reads from samples of *Mycolicibacterium smegmatis mc^2^ 155* treated with compound **3a** ([Fig. 1](#fig0001){ref-type="fig"}) -- an anti-tuberculosis drug candidate of imidazo\[1,2-*b*\]\[1,2,4,5\]tetrazines class [@bib0001] -- at a final concentration of 256 µg/ml, and untreated control samples. The sample description together with NCBI accession numbers (BioProject, BioSample and SRA) are listed in [Table 1](#tbl0001){ref-type="table"}. Sequencing and reads mapping statistics are summarized in [Table 2](#tbl0002){ref-type="table"}. Reads mapping showed 1386 differentially expressed genes (DEGs) (671 downregulated and 715 upregulated) in the experimental group as compared to the control (Supplementary Table).Fig. 1Chemical structures of the compound 3a [@bib0001].Fig. 1Table 1Details of RNA-seq data submitted to the NCBI Sequence Read Archive (SRA).Table 1Sample IDGroup**3a** concentrationBioproject accession no.Biosample accession no.SRA accession no.1--1Control0 µg/mlPRJNA615922SAMN14476747SRX80181062--1SRX80181073--1SRX80181084--1Experiment256 µg/mlSAMN14476748SRX80181095--1SRX80181106--1SRX8018111Table 2Sequencing and mapping statistics.Table 2Sample IDTotal reads(raw)Total reads (after trimming)% Aligned ReadsFragment Length (bp)1--17560,0807546,57898,0%219.02--17389,4267367,05098.2%218.13--16420,7326384,64898.5%219.44--17416,7747396,63598.8%225.85--18184,7008160,04998.9%222.46--18448,5638434,46699.1%223.1

2. Experimental design, materials, and methods {#sec0002}
==============================================

2.1. Bacterial strains and growth conditions {#sec0003}
--------------------------------------------

*M. smegmatis mc^2^ 155* strain was used in this work. *M. smegmatis* cultures were grown in Middlebrook 7H9 medium (Difco Becton Dickinson, USA) supplemented with 0.5% (v/v) glycerol and 0.05% (v/v) Tween 80 at 37 °C and 250 rpm.

2.2. Experimental design {#sec0004}
------------------------

*M. smegmatis* cultures were grown overnight in Middlebrook 7H9 broth to mid-log phase (OD600 = 1.0--1.2) and then compound **3a** dissolved in DMSO was added to the medium to a final concentration of 256 μg/ml (4 × minimal inhibitory concentration [@bib0001]) for 1.5 h. The same amount of DMSO was added to the control samples. Afterwards cells were washed twice with fresh ice-cold Middlebrook 7H9 broth and total RNA was isolated. In total, 6 RNA samples were obtained --- 3 biological replicates in the control and experimental conditions.

2.3. RNA extraction and sequencing {#sec0005}
----------------------------------

Cells from 10 mL culture were harvested by centrifugation for 10 min at 3000 × *g* and 4 °C, washed twice by 10 ml of fresh Middlebrook 7H9 broth and once by 1 ml of RNAprotect Bacteria Reagent (Qiagen, USA). Total RNA was extracted as described by Rustad et al. [@bib0003], with some modifications. In brief: *M. smegmatis* cells were homogenized in ExtractRNA reagent (Evrogen, Russia), followed by phenol (pH = 4.5)-chloroform/isoamyl alcohol (25:24:1) purification and precipitation with isopropanol (2:1, v/v). Remaining genomic DNA was removed by DNAse I, Amplification grade (Invitrogen, USA). Total RNA (1 µg) was used for library preparation. Ribosomal RNA was removed from the total RNA using the RiboMinus Transcriptome Isolation Kit, bacteria (Thermo Fisher Scientific) and libraries were prepared using the NEBNext^Ⓡ^ Ultra II Directional RNA Library Prep Kit (NEB), according to the manufacturer\'s protocol. Libraries were subsequently quantified by Quant-iT DNA Assay Kit, High Sensitivity (Thermo Fisher Scientific). Finally, equimolar quantities of all libraries (12 pM) were sequenced by a high throughput run on the Illumina HiSeq using 2 × 100 bp paired-end reads and a 5% Phix spike-in control.

2.4. Transcriptome data analysis {#sec0006}
--------------------------------

Data processing and analysis was performed as described previously by Bespyatykh et al. [@bib0004]. Raw reads' quality was assessed by FASTQC v0.11.7 [@bib0005], the remaining adapters were removed with Trimmomatic v0.33 [@bib0006]. Reads were mapped to the *M. smegmatis mc^2^ 155* reference assembly (GCF_000015005.1) and quantified with Kallisto v0.46.0 [@bib0007]. The Degust v4.1.1 web-tool [@bib0008] with integrated edgeR v3.26.8 package [@bib0009] was used for differential expression analysis. Only genes with count per million (CPM) ≥ 1 were analyzed further. Genes were filtered based on false discovery rate cutoff (FDR) ≤ 0.05 and minimum expression fold change (FC) ≥ 2.

Declaration of Competing Interest
=================================

The authors declare that they have no known competing financial interests or personal relationships which have, or could be perceived to have, influenced the work reported in this article.

Appendix. Supplementary materials {#sec0008}
=================================

Image, application 1Image, application 2

This research was funded by the Russian Science Foundation (RSF), Grant NO. 17--75--20060. We would like to thank Acad. V.N. Charushin and Prof. G.L. Rusinov of the Laboratory of Heterocyclic Compounds, Postovsky Institute of Organic Synthesis, Ural Branch of RAS, for generously providing the compound **3a** for this study.

Supplementary material associated with this article can be found, in the online version, at doi:[10.1016/j.dib.2020.105805](https://doi.org/10.1016/j.dib.2020.105805){#interref0002}.
